hpo_id,name,definition,synonyms,ref,related_diseases,related_genes
HP:0002923,Rheumatoid factor positive,The presence in the serum of an autoantibody directed against the Fc portion of IgG.,,SNOMEDCT_US:165839004|UMLS:C0151379,OMIM:615816|OMIM:601859|ORPHA:829|OMIM:603909|ORPHA:809|ORPHA:183|ORPHA:163525|ORPHA:48435|OMIM:301109|ORPHA:781|ORPHA:443811|OMIM:620376|ORPHA:90280|ORPHA:1159|ORPHA:449395|ORPHA:79099|OMIM:180300|OMIM:106300|OMIM:620321|OMIM:619632|ORPHA:91139|OMIM:618935|ORPHA:596448|ORPHA:3261|ORPHA:49041|ORPHA:728|ORPHA:90060|OMIM:209950|ORPHA:85435|OMIM:618852|OMIM:615934|ORPHA:99931|ORPHA:1304,NCBIGene:5238:PGM3|NCBIGene:356:FASLG|NCBIGene:355:FAS|NCBIGene:843:CASP10|NCBIGene:139818:DOCK11|NCBIGene:4067:LYN|NCBIGene:8838:CCN6|NCBIGene:51744:CD244|NCBIGene:26191:PTPN22|NCBIGene:4261:CIITA|NCBIGene:4795:NFKBIL1|NCBIGene:3586:IL10|NCBIGene:6583:SLC22A4|NCBIGene:3106:HLA-B|NCBIGene:713:C1QB|NCBIGene:29775:CARD10|NCBIGene:79415:CYBC1|NCBIGene:3459:IFNGR1|NCBIGene:8737:RIPK1|NCBIGene:340061:STING1
HP:0003262,Anti-smooth muscle antibody positivity,The presence in serum of antibodies against smooth muscle.,Anti-smooth muscle antibody positivity|Smooth muscle antibody positive|Smooth muscle antibody positivity,SNOMEDCT_US:310290006|UMLS:C0241185,OMIM:610163|ORPHA:99931|OMIM:603909|ORPHA:228426|ORPHA:49041|ORPHA:2137|ORPHA:781|OMIM:301109|ORPHA:1018|OMIM:601859|ORPHA:562639|ORPHA:64743,NCBIGene:919:CD247|NCBIGene:843:CASP10|NCBIGene:83737:ITCH|NCBIGene:139818:DOCK11|NCBIGene:1288:COL4A6|NCBIGene:1287:COL4A5|NCBIGene:356:FASLG|NCBIGene:355:FAS
HP:0003453,Antineutrophil antibody positivity,The presence of autoantibodies in the serum that react against neutrophils.,Antineutrophil antibodies|Neutrophil antibody positive,UMLS:C1858981,OMIM:618394|ORPHA:596448|OMIM:619573|ORPHA:60|OMIM:608710|OMIM:617718|OMIM:614420|OMIM:601859|OMIM:620825|ORPHA:536|ORPHA:2137|ORPHA:49041|ORPHA:3261|ORPHA:93552|ORPHA:486|ORPHA:90060|OMIM:603909|ORPHA:2688|ORPHA:99931|ORPHA:228426|OMIM:301078|ORPHA:464370|ORPHA:183|ORPHA:900|ORPHA:727|OMIM:256810|ORPHA:79078|OMIM:620815|OMIM:233450|ORPHA:93126|OMIM:615934|ORPHA:199241|OMIM:301109|ORPHA:48435|ORPHA:449400|OMIM:620813|ORPHA:91414,NCBIGene:60468:BACH2|NCBIGene:50619:DEF6|NCBIGene:5265:SERPINA1|NCBIGene:10095:ARPC1B|NCBIGene:1776:DNASE1L3|NCBIGene:356:FASLG|NCBIGene:355:FAS|NCBIGene:23308:ICOSLG|NCBIGene:640:BLK|NCBIGene:6696:SPP1|NCBIGene:221895:JAZF1|NCBIGene:3500:IGHG1|NCBIGene:3684:ITGAM|NCBIGene:3586:IL10|NCBIGene:51284:TLR7|NCBIGene:11277:TREX1|NCBIGene:1380:CR2|NCBIGene:2215:FCGR3B|NCBIGene:7332:UBE2L3|NCBIGene:55024:BANK1|NCBIGene:4204:MECP2|NCBIGene:720:C4A|NCBIGene:3654:IRAK1|NCBIGene:721:C4B|NCBIGene:5133:PDCD1|NCBIGene:7292:TNFSF4|NCBIGene:3663:IRF5|NCBIGene:7128:TNFAIP3|NCBIGene:6775:STAT4|NCBIGene:1773:DNASE1|NCBIGene:1493:CTLA4|NCBIGene:26191:PTPN22|NCBIGene:79932:KIAA0319L|NCBIGene:3123:HLA-DRB1|NCBIGene:10318:TNIP1|NCBIGene:2113:ETS1|NCBIGene:2213:FCGR2B|NCBIGene:54899:PXK|NCBIGene:843:CASP10|NCBIGene:6303:SAT1|NCBIGene:6728:SRP19|NCBIGene:2672:GFI1|NCBIGene:10312:TCIRG1|NCBIGene:1991:ELANE|NCBIGene:81570:CLPB|NCBIGene:83737:ITCH|NCBIGene:51311:TLR8|NCBIGene:3115:HLA-DPB1|NCBIGene:5657:PRTN3|NCBIGene:3113:HLA-DPA1|NCBIGene:4358:MPV17|NCBIGene:8625:RFXANK|NCBIGene:340061:STING1|NCBIGene:440275:EIF2AK4|NCBIGene:139818:DOCK11|NCBIGene:6891:TAP2|NCBIGene:1499:CTNNB1
HP:0003454,Platelet antibody positive,The presence in the serum of autoantibodies directed against thrombocytes.,Platelet antibody,UMLS:C1858980,OMIM:603909|OMIM:188030|OMIM:601859,NCBIGene:843:CASP10|NCBIGene:356:FASLG|NCBIGene:355:FAS
HP:0003493,Antinuclear antibody positivity,The presence of autoantibodies in the serum that react against nuclei or nuclear components.,Antinuclear antibodies|Antinuclear antibody positive|Elevated antinuclear antibody|Serum antinuclear antibody,SNOMEDCT_US:165850001|UMLS:C0151480,ORPHA:90291|OMIM:613471|ORPHA:536|ORPHA:596448|OMIM:615934|ORPHA:93126|OMIM:621018|ORPHA:50918|ORPHA:90060|OMIM:620322|OMIM:617718|ORPHA:206572|OMIM:603909|ORPHA:331235|OMIM:618534|ORPHA:85436|ORPHA:2137|ORPHA:3261|OMIM:607944|ORPHA:186|OMIM:152700|ORPHA:542643|OMIM:619375|ORPHA:1855|ORPHA:449395|OMIM:620321|OMIM:301080|OMIM:614468|ORPHA:85408|ORPHA:562639|OMIM:301109|ORPHA:470|ORPHA:449563|OMIM:614420|ORPHA:90280|ORPHA:90283|OMIM:617388|ORPHA:449400|OMIM:620514|OMIM:613495|ORPHA:93552|OMIM:618795|ORPHA:79480|ORPHA:829|OMIM:601859|OMIM:609939|OMIM:608810|ORPHA:95512|ORPHA:163525|ORPHA:199241|ORPHA:231111|OMIM:616414|OMIM:618852|ORPHA:2298|OMIM:259600|ORPHA:91355|OMIM:256810|OMIM:616744|ORPHA:79078|ORPHA:732|ORPHA:95513|OMIM:619632|OMIM:618048|ORPHA:99931|OMIM:610448|ORPHA:85410|ORPHA:728|OMIM:615559|ORPHA:48435|ORPHA:90159|ORPHA:1929|OMIM:620776|ORPHA:90002|ORPHA:289390|ORPHA:567544|ORPHA:809|ORPHA:221|OMIM:620376,NCBIGene:3930:LBR|NCBIGene:640:BLK|NCBIGene:6696:SPP1|NCBIGene:221895:JAZF1|NCBIGene:3500:IGHG1|NCBIGene:3684:ITGAM|NCBIGene:3586:IL10|NCBIGene:51284:TLR7|NCBIGene:11277:TREX1|NCBIGene:1380:CR2|NCBIGene:2215:FCGR3B|NCBIGene:7332:UBE2L3|NCBIGene:55024:BANK1|NCBIGene:4204:MECP2|NCBIGene:720:C4A|NCBIGene:3654:IRAK1|NCBIGene:721:C4B|NCBIGene:5133:PDCD1|NCBIGene:7292:TNFSF4|NCBIGene:3663:IRF5|NCBIGene:7128:TNFAIP3|NCBIGene:6775:STAT4|NCBIGene:1773:DNASE1|NCBIGene:1493:CTLA4|NCBIGene:26191:PTPN22|NCBIGene:79932:KIAA0319L|NCBIGene:3123:HLA-DRB1|NCBIGene:10318:TNIP1|NCBIGene:2113:ETS1|NCBIGene:2213:FCGR2B|NCBIGene:54899:PXK|NCBIGene:340061:STING1|NCBIGene:129607:CMPK2|NCBIGene:714:C1QC|NCBIGene:10095:ARPC1B|NCBIGene:843:CASP10|NCBIGene:10125:RASGRP1|NCBIGene:355:FAS|NCBIGene:356:FASLG|NCBIGene:54:ACP5|NCBIGene:5450:POU2AF1|NCBIGene:3594:IL12RB1|NCBIGene:23534:TNPO3|NCBIGene:6689:SPIB|NCBIGene:79258:MMEL1|NCBIGene:9966:TNFSF15|NCBIGene:3592:IL12A|NCBIGene:2212:FCGR2A|NCBIGene:8651:SOCS1|NCBIGene:713:C1QB|NCBIGene:5336:PLCG2|NCBIGene:919:CD247|NCBIGene:79722:ANKRD55|NCBIGene:3560:IL2RB|NCBIGene:3559:IL2RA|NCBIGene:5771:PTPN2|NCBIGene:139818:DOCK11|NCBIGene:9056:SLC7A7|NCBIGene:1776:DNASE1L3|NCBIGene:22861:NLRP1|NCBIGene:5335:PLCG1|NCBIGene:931:MS4A1|NCBIGene:6303:SAT1|NCBIGene:144811:LACC1|NCBIGene:1410:CRYAB|NCBIGene:440275:EIF2AK4|NCBIGene:1314:COPA|NCBIGene:8737:RIPK1|NCBIGene:4313:MMP2|NCBIGene:4358:MPV17|NCBIGene:29775:CARD10|NCBIGene:51371:POMP|NCBIGene:5580:PRKCD|NCBIGene:2582:GALE|NCBIGene:4067:LYN
HP:0003613,Antiphospholipid antibody positivity,The presence of circulating autoantibodies to phospholipids.,Antiphospholipid antibodies|Antiphospholipid antibody|Phospholipid antibody positivity,UMLS:C4019436,ORPHA:391487|ORPHA:93552|OMIM:601859|OMIM:182410|ORPHA:227982|ORPHA:90280|OMIM:615934|ORPHA:781|OMIM:152700|ORPHA:439167|OMIM:225750|ORPHA:80|ORPHA:820|ORPHA:3261|ORPHA:464343|OMIM:603909|ORPHA:70591|ORPHA:163525|ORPHA:227990|ORPHA:90060|OMIM:615559|ORPHA:64743|OMIM:619573,NCBIGene:6772:STAT1|NCBIGene:6775:STAT4|NCBIGene:6696:SPP1|NCBIGene:6303:SAT1|NCBIGene:3654:IRAK1|NCBIGene:356:FASLG|NCBIGene:355:FAS|NCBIGene:51816:ADA2|NCBIGene:340061:STING1|NCBIGene:2213:FCGR2B|NCBIGene:2212:FCGR2A|NCBIGene:1493:CTLA4|NCBIGene:26191:PTPN22|NCBIGene:11277:TREX1|NCBIGene:1773:DNASE1|NCBIGene:843:CASP10|NCBIGene:5580:PRKCD|NCBIGene:50619:DEF6
HP:0020050,Anti-granulocyte-macrophage colony stimulating factor antibody positivity,The presence of autoantibodies in the serum that react against granulocyte-macrophage colony stimulating factor.,Anti-GM-CSF antibody positivity,,OMIM:610910|OMIM:614370,NCBIGene:1439:CSF2RB
HP:0020136,Anticardiolipin IgG antibody positivity,The presence of circulating IgG autoantibodies to cardiolipin.,,,ORPHA:80|ORPHA:781|OMIM:615559|ORPHA:464343|ORPHA:64743|OMIM:619573,NCBIGene:5580:PRKCD|NCBIGene:50619:DEF6
HP:0020137,Anticardiolipin IgM antibody positivity,The presence of circulating IgM autoantibodies to cardiolipin.,,,ORPHA:64743|ORPHA:464343|ORPHA:80,
HP:0020151,Anti-dsDNA antibody positivity,The presence of autoantibodies (immunoglobulins) in the serum that react against double-stranded DNA.,Anti-double-stranded DNA antibody positivity,,ORPHA:90002|ORPHA:1855|ORPHA:289390|ORPHA:567544|ORPHA:536|ORPHA:470|OMIM:619375|ORPHA:163525|ORPHA:1929|ORPHA:809|ORPHA:90283|OMIM:614420,NCBIGene:54:ACP5|NCBIGene:640:BLK|NCBIGene:6696:SPP1|NCBIGene:221895:JAZF1|NCBIGene:3500:IGHG1|NCBIGene:3684:ITGAM|NCBIGene:3586:IL10|NCBIGene:51284:TLR7|NCBIGene:11277:TREX1|NCBIGene:1380:CR2|NCBIGene:2215:FCGR3B|NCBIGene:7332:UBE2L3|NCBIGene:55024:BANK1|NCBIGene:4204:MECP2|NCBIGene:720:C4A|NCBIGene:3654:IRAK1|NCBIGene:721:C4B|NCBIGene:5133:PDCD1|NCBIGene:7292:TNFSF4|NCBIGene:3663:IRF5|NCBIGene:7128:TNFAIP3|NCBIGene:6775:STAT4|NCBIGene:1773:DNASE1|NCBIGene:1493:CTLA4|NCBIGene:26191:PTPN22|NCBIGene:79932:KIAA0319L|NCBIGene:3123:HLA-DRB1|NCBIGene:10318:TNIP1|NCBIGene:2113:ETS1|NCBIGene:2213:FCGR2B|NCBIGene:54899:PXK|NCBIGene:9056:SLC7A7|NCBIGene:8651:SOCS1|NCBIGene:1776:DNASE1L3
HP:0025329,Anti-glutamic acid decarboxylase antibody positivity,The presence of autoantibodies (immunoglobulins) in the serum that react against glutamic acid decarboxylase.,Anti-GAD antibody positivity,,OMIM:621004|OMIM:610582|ORPHA:228426|ORPHA:443804|OMIM:620044|OMIM:304790|OMIM:612225|ORPHA:3002|OMIM:616329,NCBIGene:5133:PDCD1|NCBIGene:3767:KCNJ11|NCBIGene:83737:ITCH|NCBIGene:1854:DUT|NCBIGene:50943:FOXP3|NCBIGene:5078:PAX4|NCBIGene:9103:FCGR2C
HP:0025343,Lupus anticoagulant,"Presence of lupus anticoagulant (LA) autoantibodies. LA represent a heterogeneous group of autoantibodies, IgG, IgM, or a mixture of both classes, that interfere with standard phospholipid-based coagulant tests (this is only an in vitro phenomenon, LA do not cause reduction of coagulation in vivo). The antibodies are directed against plasma proteins which also bind to phospholipid surfaces.",,,OMIM:107320|ORPHA:231111|ORPHA:93552|OMIM:616744|OMIM:615688|ORPHA:464343|ORPHA:70591|ORPHA:80|ORPHA:542643|OMIM:620376|ORPHA:781,NCBIGene:6775:STAT4|NCBIGene:6696:SPP1|NCBIGene:6303:SAT1|NCBIGene:3654:IRAK1|NCBIGene:7128:TNFAIP3|NCBIGene:51816:ADA2|NCBIGene:4067:LYN
HP:0025353,Anti-multiple nuclear dots antibody positivity,"A type of antinuclear antibody (ANA) positivity revealed by indirect immunofluorescence (IFL). The multiple nuclear dots (MND) pattern is immunomorphologically characterized by the staining of 3-20 dots of variable size distributed all over the cell nucleus, but sparing the nucleoli, and, in contrast to the anticentromere pattern, MND reactivity does not stain the chromosomes in mitotic cells.",Anti-MND antibodies,,ORPHA:562639,
HP:0025379,Anti-thyroid peroxidase antibody positivity,The presence of autoantibodies (immunoglobulins) in the serum that react against thyroid peroxidase.,Anti-TPO antibody positivity|Antimicrosomal antibodies|Antimicrosomal antibody positivity|TPOAbs,,ORPHA:277|OMIM:240300|ORPHA:525731|ORPHA:49041|ORPHA:95715|OMIM:618534|OMIM:274300|ORPHA:37042|OMIM:618048|ORPHA:228426|ORPHA:566243|ORPHA:95719|OMIM:615577|OMIM:610199|OMIM:301109|ORPHA:64744|ORPHA:3002|OMIM:620376|OMIM:609152,NCBIGene:100:ADA|NCBIGene:326:AIRE|NCBIGene:10125:RASGRP1|NCBIGene:7068:THRB|NCBIGene:50943:FOXP3|NCBIGene:51371:POMP|NCBIGene:83737:ITCH|NCBIGene:4791:NFKB2|NCBIGene:169792:GLIS3|NCBIGene:139818:DOCK11|NCBIGene:9103:FCGR2C|NCBIGene:4067:LYN|NCBIGene:7253:TSHR
HP:0025381,Anti-pituitary antibody positivity,"Circulating antipituitary antibodies (APA) are markers of autoimmune hypophysitis, which may cause deficient pituitary function.",,,,
HP:0025440,Warm reactive autoantibody positivity,Warm reactive autoantibodies are RBC-directed immune responses that are maximally reactive at 37 degrees C.,,,,
HP:0025629,Anti-myelin-associated glycoprotein antibody positivity,The presence of autoantibodies (immunoglobulins) in the serum that react against myelin-associated glycoprotein (MAG).,,,,
HP:0025731,Anti-glycosylphosphatidylinositol anchored high-density lipoprotein binding protein 1 antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against glycosylphosphatidylinositol anchored high-density lipoprotein binding protein 1.,Anti-GPIHBP1 antibody positivity,,,
HP:0025762,Anti-ganglionic acetylcholine receptor antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against acetylcholine receptors of the ganglionic type.,,,,
HP:0030057,Autoimmune antibody positivity,The presence of an antibody in the blood circulation that is directed against the organism's own cells or tissues.,,UMLS:C4022660,ORPHA:90291|OMIM:613471|ORPHA:3453|OMIM:240300|ORPHA:85138|ORPHA:703|ORPHA:43393|ORPHA:97560|ORPHA:221|ORPHA:80|ORPHA:464343|ORPHA:95719|ORPHA:566243|OMIM:274300|OMIM:618534|OMIM:618048|OMIM:619632|OMIM:609152|OMIM:615577|ORPHA:3002|OMIM:301109|ORPHA:64744|OMIM:620757|OMIM:233450|OMIM:620475|ORPHA:623626|OMIM:301080|OMIM:618394|ORPHA:596448|OMIM:619573|ORPHA:60|OMIM:608710|OMIM:617718|OMIM:614420|ORPHA:732|ORPHA:81|ORPHA:277|ORPHA:525731|ORPHA:49041|ORPHA:95715|ORPHA:37042|ORPHA:228426|OMIM:610199|OMIM:620376|ORPHA:536|ORPHA:704|ORPHA:562639|ORPHA:2137|ORPHA:589|ORPHA:289390|ORPHA:90002|ORPHA:809|ORPHA:206572|ORPHA:54370|ORPHA:329918|ORPHA:1656|OMIM:616325|ORPHA:2932|ORPHA:3198|ORPHA:443804|ORPHA:90033|ORPHA:71275|ORPHA:206569|ORPHA:398063|ORPHA:555905|ORPHA:227990|OMIM:140300|ORPHA:79444|ORPHA:90283|ORPHA:94089|ORPHA:60026|ORPHA:79128|OMIM:301054|ORPHA:79443|ORPHA:90673|ORPHA:824|OMIM:620795|ORPHA:88|ORPHA:231111|ORPHA:71211|ORPHA:264675|ORPHA:293978|ORPHA:747|ORPHA:75565|ORPHA:71505|ORPHA:411593|ORPHA:94090|ORPHA:424|ORPHA:99885|ORPHA:99931|ORPHA:398124|OMIM:169610|ORPHA:1183|ORPHA:90674|ORPHA:99886|ORPHA:99832|ORPHA:79138|ORPHA:306550|ORPHA:227982|ORPHA:98818|OMIM:109100|ORPHA:95717|ORPHA:3386|ORPHA:99819|ORPHA:552|ORPHA:90003|ORPHA:79134|ORPHA:36913|ORPHA:46488|ORPHA:1855|ORPHA:567544|ORPHA:470|OMIM:619375|ORPHA:163525|ORPHA:1929|OMIM:601859|OMIM:620825|ORPHA:3261|ORPHA:93552|ORPHA:486|ORPHA:90060|OMIM:603909|ORPHA:2688|OMIM:301078|ORPHA:464370|ORPHA:623615|ORPHA:84142|ORPHA:83467|ORPHA:611|OMIM:610910|OMIM:614370|ORPHA:391487|OMIM:182410|ORPHA:90280|OMIM:615934|ORPHA:781|OMIM:152700|ORPHA:439167|OMIM:225750|ORPHA:820|ORPHA:70591|ORPHA:93126|OMIM:621018|ORPHA:50918|OMIM:620322|ORPHA:331235|ORPHA:85436|OMIM:607944|ORPHA:186|ORPHA:542643|ORPHA:449395|OMIM:620321|OMIM:614468|ORPHA:85408|ORPHA:449563|OMIM:617388|ORPHA:449400|OMIM:620514|OMIM:613495|OMIM:618795|ORPHA:79480|ORPHA:829|OMIM:609939|OMIM:608810|ORPHA:95512|ORPHA:199241|OMIM:616414|OMIM:618852|ORPHA:2298|OMIM:259600|ORPHA:91355|OMIM:256810|OMIM:616744|ORPHA:79078|ORPHA:95513|OMIM:610448|ORPHA:85410|ORPHA:728|OMIM:615559|ORPHA:48435|ORPHA:90159|OMIM:620776|ORPHA:64743|ORPHA:3143|OMIM:621004|ORPHA:183|ORPHA:900|ORPHA:727|OMIM:241850|OMIM:188030|ORPHA:98919|OMIM:180300|OMIM:610582|OMIM:620044|OMIM:304790|OMIM:612225|OMIM:616329|OMIM:107320|OMIM:615688|ORPHA:217253|OMIM:616033|OMIM:610163|OMIM:616192|ORPHA:548|ORPHA:208999|OMIM:620815|OMIM:620813|ORPHA:1018|ORPHA:91414|ORPHA:139417|ORPHA:83597|OMIM:615816|ORPHA:443811|ORPHA:1159|ORPHA:79099|OMIM:106300|ORPHA:91139|OMIM:618935|OMIM:209950|ORPHA:85435|ORPHA:1304|OMIM:616313|OMIM:616323|OMIM:616227|OMIM:254300|OMIM:614198|ORPHA:99867|OMIM:254210|OMIM:603034|OMIM:616224|ORPHA:590|OMIM:616314|OMIM:601462|OMIM:608930|ORPHA:98914|ORPHA:254361|OMIM:616326|OMIM:616324,NCBIGene:3930:LBR|NCBIGene:326:AIRE|NCBIGene:3119:HLA-DQB1|NCBIGene:3123:HLA-DRB1|NCBIGene:7068:THRB|NCBIGene:10125:RASGRP1|NCBIGene:51371:POMP|NCBIGene:29775:CARD10|NCBIGene:7253:TSHR|NCBIGene:4791:NFKB2|NCBIGene:9103:FCGR2C|NCBIGene:139818:DOCK11|NCBIGene:10020:GNE|NCBIGene:60:ACTB|NCBIGene:51284:TLR7|NCBIGene:60468:BACH2|NCBIGene:50619:DEF6|NCBIGene:5265:SERPINA1|NCBIGene:10095:ARPC1B|NCBIGene:1776:DNASE1L3|NCBIGene:100:ADA|NCBIGene:50943:FOXP3|NCBIGene:83737:ITCH|NCBIGene:169792:GLIS3|NCBIGene:4067:LYN|NCBIGene:640:BLK|NCBIGene:6696:SPP1|NCBIGene:221895:JAZF1|NCBIGene:3500:IGHG1|NCBIGene:3684:ITGAM|NCBIGene:3586:IL10|NCBIGene:11277:TREX1|NCBIGene:1380:CR2|NCBIGene:2215:FCGR3B|NCBIGene:7332:UBE2L3|NCBIGene:55024:BANK1|NCBIGene:4204:MECP2|NCBIGene:720:C4A|NCBIGene:3654:IRAK1|NCBIGene:721:C4B|NCBIGene:5133:PDCD1|NCBIGene:7292:TNFSF4|NCBIGene:3663:IRF5|NCBIGene:7128:TNFAIP3|NCBIGene:6775:STAT4|NCBIGene:1773:DNASE1|NCBIGene:1493:CTLA4|NCBIGene:26191:PTPN22|NCBIGene:79932:KIAA0319L|NCBIGene:10318:TNIP1|NCBIGene:2113:ETS1|NCBIGene:2213:FCGR2B|NCBIGene:54899:PXK|NCBIGene:4593:MUSK|NCBIGene:6006:RHCE|NCBIGene:6007:RHD|NCBIGene:6005:RHAG|NCBIGene:2778:GNAS|NCBIGene:8675:STX16|NCBIGene:7317:UBA1|NCBIGene:54790:TET2|NCBIGene:811:CALR|NCBIGene:3717:JAK2|NCBIGene:4352:MPL|NCBIGene:81858:SHARPIN|NCBIGene:7012:TERC|NCBIGene:7015:TERT|NCBIGene:5551:PRF1|NCBIGene:3458:IFNG|NCBIGene:51119:SBDS|NCBIGene:1439:CSF2RB|NCBIGene:1438:CSF2RA|NCBIGene:3767:KCNJ11|NCBIGene:6833:ABCC8|NCBIGene:3651:PDX1|NCBIGene:2645:GCK|NCBIGene:6774:STAT3|NCBIGene:3630:INS|NCBIGene:7252:TSHB|NCBIGene:346171:ZFP57|NCBIGene:5325:PLAGL1|NCBIGene:57061:HYMAI|NCBIGene:7201:TRHR|NCBIGene:8772:FADD|NCBIGene:2903:GRIN2A|NCBIGene:3172:HNF4A|NCBIGene:6927:HNF1A|NCBIGene:4760:NEUROD1|NCBIGene:1056:CEL|NCBIGene:8462:KLF11|NCBIGene:26060:APPL1|NCBIGene:5078:PAX4|NCBIGene:79731:NARS2|NCBIGene:54:ACP5|NCBIGene:9056:SLC7A7|NCBIGene:8651:SOCS1|NCBIGene:356:FASLG|NCBIGene:355:FAS|NCBIGene:23308:ICOSLG|NCBIGene:843:CASP10|NCBIGene:6303:SAT1|NCBIGene:6728:SRP19|NCBIGene:2672:GFI1|NCBIGene:10312:TCIRG1|NCBIGene:1991:ELANE|NCBIGene:81570:CLPB|NCBIGene:51311:TLR8|NCBIGene:6772:STAT1|NCBIGene:51816:ADA2|NCBIGene:340061:STING1|NCBIGene:2212:FCGR2A|NCBIGene:129607:CMPK2|NCBIGene:714:C1QC|NCBIGene:5450:POU2AF1|NCBIGene:3594:IL12RB1|NCBIGene:23534:TNPO3|NCBIGene:6689:SPIB|NCBIGene:79258:MMEL1|NCBIGene:9966:TNFSF15|NCBIGene:3592:IL12A|NCBIGene:713:C1QB|NCBIGene:5336:PLCG2|NCBIGene:919:CD247|NCBIGene:79722:ANKRD55|NCBIGene:3560:IL2RB|NCBIGene:3559:IL2RA|NCBIGene:5771:PTPN2|NCBIGene:22861:NLRP1|NCBIGene:5335:PLCG1|NCBIGene:931:MS4A1|NCBIGene:144811:LACC1|NCBIGene:1410:CRYAB|NCBIGene:440275:EIF2AK4|NCBIGene:1314:COPA|NCBIGene:8737:RIPK1|NCBIGene:4313:MMP2|NCBIGene:4358:MPV17|NCBIGene:5580:PRKCD|NCBIGene:2582:GALE|NCBIGene:3115:HLA-DPB1|NCBIGene:5657:PRTN3|NCBIGene:3113:HLA-DPA1|NCBIGene:2304:FOXE1|NCBIGene:51744:CD244|NCBIGene:4261:CIITA|NCBIGene:4795:NFKBIL1|NCBIGene:6583:SLC22A4|NCBIGene:1854:DUT|NCBIGene:93587:TRMT10A|NCBIGene:5611:DNAJC3|NCBIGene:8625:RFXANK|NCBIGene:6891:TAP2|NCBIGene:1288:COL4A6|NCBIGene:1287:COL4A5|NCBIGene:1499:CTNNB1|NCBIGene:5238:PGM3|NCBIGene:8838:CCN6|NCBIGene:3106:HLA-B|NCBIGene:79415:CYBC1|NCBIGene:3459:IFNGR1|NCBIGene:1140:CHRNB1|NCBIGene:1144:CHRND|NCBIGene:199857:ALG14|NCBIGene:285489:DOK7|NCBIGene:6329:SCN4A|NCBIGene:1103:CHAT|NCBIGene:8292:COLQ|NCBIGene:9581:PREPL|NCBIGene:1134:CHRNA1|NCBIGene:1305:COL13A1|NCBIGene:6616:SNAP25|NCBIGene:4649:MYO9A|NCBIGene:6843:VAMP1|NCBIGene:375790:AGRN|NCBIGene:60482:SLC5A7|NCBIGene:6572:SLC18A3|NCBIGene:6576:SLC25A1|NCBIGene:127833:SYT2|NCBIGene:5339:PLEC|NCBIGene:5913:RAPSN|NCBIGene:1145:CHRNE
HP:0030167,Antimitochondrial antibody positivity,The presence of autoantibodies (immunoglobulins) in the serum that react against mitochondria.,Serum antimitochrondrial antibodies,UMLS:C4021051,OMIM:620376|ORPHA:562639|OMIM:610163|OMIM:613471|ORPHA:186,NCBIGene:4067:LYN|NCBIGene:919:CD247|NCBIGene:3930:LBR|NCBIGene:5450:POU2AF1|NCBIGene:3594:IL12RB1|NCBIGene:23534:TNPO3|NCBIGene:3663:IRF5|NCBIGene:6689:SPIB|NCBIGene:79258:MMEL1|NCBIGene:9966:TNFSF15|NCBIGene:3592:IL12A
HP:0030208,Anti-neuromuscular Junction acetylcholine receptor antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against neuromuscular junction acetylcholine receptors.,Acetylcholine receptor antibody positivity|Anti-AChR antibody positivity,UMLS:C4022578,OMIM:616313|OMIM:616325|OMIM:616323|OMIM:616227|OMIM:254300|ORPHA:589|OMIM:614198|ORPHA:99867|ORPHA:79480|OMIM:254210|OMIM:603034|OMIM:616224|ORPHA:590|OMIM:616314|OMIM:601462|OMIM:608930|ORPHA:98914|ORPHA:254361|OMIM:616326|OMIM:616324,NCBIGene:1140:CHRNB1|NCBIGene:4593:MUSK|NCBIGene:1144:CHRND|NCBIGene:199857:ALG14|NCBIGene:285489:DOK7|NCBIGene:6329:SCN4A|NCBIGene:1103:CHAT|NCBIGene:8292:COLQ|NCBIGene:9581:PREPL|NCBIGene:1134:CHRNA1|NCBIGene:1305:COL13A1|NCBIGene:6616:SNAP25|NCBIGene:4649:MYO9A|NCBIGene:6843:VAMP1|NCBIGene:375790:AGRN|NCBIGene:60482:SLC5A7|NCBIGene:6572:SLC18A3|NCBIGene:6576:SLC25A1|NCBIGene:127833:SYT2|NCBIGene:5339:PLEC|NCBIGene:5913:RAPSN|NCBIGene:1145:CHRNE
HP:0030209,Calcium channel antibody positivity,The presence of autoantibodies (immunoglobulins) in the serum that react against voltage-gated calcium channels.,Ca channel antibody positivity|Ca2+ channel antibody positivity,UMLS:C4022577,ORPHA:43393,
HP:0030210,Anti-muscle-specific tyrosine kinase antibody,The presence of autoantibodies (immunoglobulins) in the serum that react against muscle specific kinase (anti-MuSK Ab).,Anti-MUSK antibodies|Anti-muscle-specific tyrosine kinase antibody|Muscle specific kinase antibody positivity,UMLS:C4021044,ORPHA:589|OMIM:616325,NCBIGene:4593:MUSK
HP:0030859,Anti-topoisomerase I antibody positivity,The presence of autoantibodies (immunoglobulins) in the serum that react against topoisomerase I.,Anti-Scl-70 antibody positivity|Top1 antibody positivity|Topoisomerase (DNA) I antibody positivity,UMLS:C4280741,ORPHA:90291|ORPHA:206572,
HP:0030873,Anti-centromere antibody positivity,The presence of autoantibodies (immunoglobulins) in the serum that react against the centromeres or centromere components.,ACA positivity|Anticentromere antibody positivity,UMLS:C4280732,ORPHA:90291|OMIM:613471,NCBIGene:3930:LBR
HP:0030888,C3 nephritic factor positivity,The presence of autoantibodies (immunoglobulins) in the serum that react against C3 convertase (C3bBb).,,,ORPHA:54370|ORPHA:329918,
HP:0030908,Liver kidney microsome type 1 antibody positivity,"The presence of autoantibodies (immunoglobulins) in the serum that react against P450 2D6, a cytochrome P450 mono-oxygenase. Anti-LKM-1 antibodies are considered to be a diagnostic marker of autoimmune hepatitis type 2 (AIH2).",Anti-LKM-1 positive|Anti-LKM1 antibody positivity|Anti-liver kidney microsomal type 1 antibody positivity|Anti-type I liver-kidney microsomal antibody positivity,,ORPHA:562639|ORPHA:2137|ORPHA:3002,NCBIGene:9103:FCGR2C
HP:0030909,Anti-liver cytosolic antigen type 1 antibody positivity,The presence of autoantibodies (immunoglobulins) in the serum that react against a 60-kd peptide contained in the liver cytosolic fraction.,Anti-liver cytosol antibody-1 positivity,,ORPHA:562639|ORPHA:37042|ORPHA:2137,NCBIGene:50943:FOXP3
HP:0031104,Insulin receptor antibody positivity,The presence of autoantibodies (immunoglobulins) in the serum that react against the insulin receptor.,,,ORPHA:37042|ORPHA:228426,NCBIGene:50943:FOXP3|NCBIGene:83737:ITCH
HP:0031810,Anti-ganglioside antibody positivity,The presence of autoantibodies (immunoglobulins) in the serum that react to gangliosides.,,,ORPHA:98919,
HP:0031907,Anti-mitochondrial M2 antibody positivity,The presence of M2 anti-mitochondrial antibody (immunoglobulins) in the serum.,AMA-M2 positive,,,
HP:0032069,Anti-thyroglobulin antibody positivity,The presence of autoantibodies (immunoglobulins) in the serum that react to thyroglobulin.,Anti-thyroid globulin antibody positivity|TgAbs,,ORPHA:95719|ORPHA:566243|OMIM:274300|OMIM:618534|OMIM:618048|OMIM:619632|OMIM:609152|OMIM:615577|ORPHA:3002|OMIM:240300|OMIM:301109|ORPHA:64744,NCBIGene:7068:THRB|NCBIGene:10125:RASGRP1|NCBIGene:51371:POMP|NCBIGene:29775:CARD10|NCBIGene:7253:TSHR|NCBIGene:4791:NFKB2|NCBIGene:9103:FCGR2C|NCBIGene:326:AIRE|NCBIGene:139818:DOCK11
HP:0032229,Perinuclear antineutrophil antibody positivity,The presence of autoantibodies in the serum that react against proteins predominantly expressed in perinuclear region of neutrophils.,p-ANCA positivity,,OMIM:618394|ORPHA:596448|OMIM:619573|ORPHA:60|OMIM:608710|OMIM:617718|OMIM:614420|ORPHA:91414|ORPHA:183|ORPHA:900|ORPHA:727|OMIM:233450,NCBIGene:60468:BACH2|NCBIGene:50619:DEF6|NCBIGene:5265:SERPINA1|NCBIGene:10095:ARPC1B|NCBIGene:1776:DNASE1L3|NCBIGene:1499:CTNNB1|NCBIGene:3115:HLA-DPB1|NCBIGene:26191:PTPN22|NCBIGene:1493:CTLA4|NCBIGene:5657:PRTN3|NCBIGene:3113:HLA-DPA1
HP:0032230,Cytoplasmic antineutrophil antibody positivity,The presence of autoantibodies in the serum that react against proteins predominantly expressed in cytoplasmic granules of neutrophils.,Anti-neutrophil cytoplasmic antibody positivity|C-ANCA antibodies|Cytoplasmic antineutrophil cytoplasmic antibodies,,OMIM:256810|ORPHA:79078|ORPHA:727|OMIM:620815|OMIM:233450|ORPHA:93126|ORPHA:183|OMIM:615934|ORPHA:199241|OMIM:301109|ORPHA:900|ORPHA:48435|ORPHA:449400|OMIM:620813|OMIM:608710,NCBIGene:4358:MPV17|NCBIGene:8625:RFXANK|NCBIGene:340061:STING1|NCBIGene:440275:EIF2AK4|NCBIGene:139818:DOCK11|NCBIGene:3115:HLA-DPB1|NCBIGene:26191:PTPN22|NCBIGene:1493:CTLA4|NCBIGene:5657:PRTN3|NCBIGene:3113:HLA-DPA1|NCBIGene:6891:TAP2
HP:0032235,Anti-La/SS-B antibody positivity,The presence of autoantibodies in the blood circulation that react against La/SSB autoantigens.,,,ORPHA:163525|ORPHA:596448|ORPHA:536|ORPHA:90283,NCBIGene:640:BLK|NCBIGene:6696:SPP1|NCBIGene:221895:JAZF1|NCBIGene:3500:IGHG1|NCBIGene:3684:ITGAM|NCBIGene:3586:IL10|NCBIGene:51284:TLR7|NCBIGene:11277:TREX1|NCBIGene:1380:CR2|NCBIGene:2215:FCGR3B|NCBIGene:7332:UBE2L3|NCBIGene:55024:BANK1|NCBIGene:4204:MECP2|NCBIGene:720:C4A|NCBIGene:3654:IRAK1|NCBIGene:721:C4B|NCBIGene:5133:PDCD1|NCBIGene:7292:TNFSF4|NCBIGene:3663:IRF5|NCBIGene:7128:TNFAIP3|NCBIGene:6775:STAT4|NCBIGene:1773:DNASE1|NCBIGene:1493:CTLA4|NCBIGene:26191:PTPN22|NCBIGene:79932:KIAA0319L|NCBIGene:3123:HLA-DRB1|NCBIGene:10318:TNIP1|NCBIGene:2113:ETS1|NCBIGene:2213:FCGR2B|NCBIGene:54899:PXK
HP:0032264,Anti-NMDA receptor antibody positivity,The presence of autoantibodies (immunoglobulins) in the serum that react against the NMDA (N-methyl-D-aspartate)-type glutamate receptor.,Presence of anti-N-methyl-D-aspartate Receptor antibody in blood|Presence of anti-NMDAR antibody in blood,,ORPHA:217253,
HP:0032366,Positive direct antiglobulin test,"A positive result of the direct antiglobulin test (DAT), a method of demonstrating the presence of antibody or complement bound to red blood cell (RBC) membranes by the use of anti-human globulin to form a visible agglutination reaction.",,,ORPHA:90033|ORPHA:71275,NCBIGene:6006:RHCE|NCBIGene:6007:RHD|NCBIGene:6005:RHAG
HP:0032376,Anti-beta 2 glycoprotein I antibody positivity,Presence of antibodies against beta 2 glycoprotein I in the circulation. Beta-2 glycoprotein I (beta2GPI) is the principal target of autoantibodies in the antiphospholipid syndrome (APS).,Anti-B2GPI positivity,,ORPHA:80|ORPHA:464343|OMIM:618048,NCBIGene:51371:POMP
HP:0032469,Anti-asialoglycoprotein receptor antibody positivity,Presence of autoantibodies against the asialoglycoprotein receptor (ASGPR) in the blood circulation.,,,ORPHA:2137,
HP:0032492,Anti-myelin oligodendrocyte glycoprotein antibody positivity,Presence of antibodies in the serum that react against myelin oligodendrocyte glycoprotein.,Anti-MOG antibody positivity,,ORPHA:83597,
HP:0033028,Anti-U1 ribonucleoprotein antibody positivity,"The presence autoantibodies in the serum that react to proteins (70 Kd, A, C) that are associated with U1 RNA and form U1snRNP.",Anti-RNP-antibodies|Anti-U1-RNP antibody positivity,,ORPHA:809|ORPHA:596448|OMIM:619375|ORPHA:536|OMIM:301109,NCBIGene:8651:SOCS1|NCBIGene:640:BLK|NCBIGene:6696:SPP1|NCBIGene:221895:JAZF1|NCBIGene:3500:IGHG1|NCBIGene:3684:ITGAM|NCBIGene:3586:IL10|NCBIGene:51284:TLR7|NCBIGene:11277:TREX1|NCBIGene:1380:CR2|NCBIGene:2215:FCGR3B|NCBIGene:7332:UBE2L3|NCBIGene:55024:BANK1|NCBIGene:4204:MECP2|NCBIGene:720:C4A|NCBIGene:3654:IRAK1|NCBIGene:721:C4B|NCBIGene:5133:PDCD1|NCBIGene:7292:TNFSF4|NCBIGene:3663:IRF5|NCBIGene:7128:TNFAIP3|NCBIGene:6775:STAT4|NCBIGene:1773:DNASE1|NCBIGene:1493:CTLA4|NCBIGene:26191:PTPN22|NCBIGene:79932:KIAA0319L|NCBIGene:3123:HLA-DRB1|NCBIGene:10318:TNIP1|NCBIGene:2113:ETS1|NCBIGene:2213:FCGR2B|NCBIGene:54899:PXK|NCBIGene:139818:DOCK11
HP:0033030,Anti-glomerular basement membrane-antibody positivity,The presence of autoantibodies in the serum that react to the glomerular basement membrane.,Anti-GBM-antibody positivity,,OMIM:233450,
HP:0033033,Anti-MDA5 antibody positivity,The presence of autoantibodies in the serum that react to Anti-MDA5 (Anti-melanoma differentiation-associated proteine 5).,Increased level of anti-melanoma differentiation-associated protein 5 antibodies,,ORPHA:221,
HP:0033034,Anti-citrullinated protein antibody positivity,"The presence autoantibodies in the serum that react do different citrullinated antigens, including filaggrin, fibrinogen, vimentin and collagen.",,,OMIM:180300,NCBIGene:51744:CD244|NCBIGene:26191:PTPN22|NCBIGene:4261:CIITA|NCBIGene:4795:NFKBIL1|NCBIGene:3586:IL10|NCBIGene:6583:SLC22A4
HP:0033038,Anti-RNA-polymerase-III-autoantibody positivity,The presence of autoantibodies in the serum that react to RNA-polymerase III.,,,ORPHA:90291,
HP:0033040,Anti-Sm antibody positivity,The presence of autoantibodies in the serum that react to seven proteins that consist of a core of small nuclear ribonucleoprotein (snRNP) particles.,Anti-Smith autoantibody,,ORPHA:596448|ORPHA:206572|ORPHA:536|OMIM:620376|OMIM:620321,NCBIGene:640:BLK|NCBIGene:6696:SPP1|NCBIGene:221895:JAZF1|NCBIGene:3500:IGHG1|NCBIGene:3684:ITGAM|NCBIGene:3586:IL10|NCBIGene:51284:TLR7|NCBIGene:11277:TREX1|NCBIGene:1380:CR2|NCBIGene:2215:FCGR3B|NCBIGene:7332:UBE2L3|NCBIGene:55024:BANK1|NCBIGene:4204:MECP2|NCBIGene:720:C4A|NCBIGene:3654:IRAK1|NCBIGene:721:C4B|NCBIGene:5133:PDCD1|NCBIGene:7292:TNFSF4|NCBIGene:3663:IRF5|NCBIGene:7128:TNFAIP3|NCBIGene:6775:STAT4|NCBIGene:1773:DNASE1|NCBIGene:1493:CTLA4|NCBIGene:26191:PTPN22|NCBIGene:79932:KIAA0319L|NCBIGene:3123:HLA-DRB1|NCBIGene:10318:TNIP1|NCBIGene:2113:ETS1|NCBIGene:2213:FCGR2B|NCBIGene:54899:PXK|NCBIGene:4067:LYN|NCBIGene:713:C1QB
HP:0033342,Anti-aquaporin 4 antibody positivity,The presence of autoantibodies (immunoglobulins) in the serum that react against aquaporin-4.,Anti-AQP4 antibody positivity,,OMIM:301080,NCBIGene:51284:TLR7
HP:0033394,Anti-carbonic anhydrase II antibody positivity,The presence of autoantibodies (immunoglobulins) in the serum that react against carbonic anhydrase II.,,,ORPHA:90291,
HP:0033395,Antilactoferrin antibody positivity,The presence of autoantibodies (immunoglobulins) in the serum that react against lactoferrin.,,,,
HP:0033476,Extractable nuclear antigen positivity,The presence of autoantibodies in the serum that react against extractable nuclear components that are referred to as extractable because they can be extracted from cell nuclei with saline solution.,,,OMIM:620321|ORPHA:163525|ORPHA:596448|ORPHA:536|ORPHA:90283|ORPHA:90291|ORPHA:206572|ORPHA:809|OMIM:619375|OMIM:301109|OMIM:620376|ORPHA:289390,NCBIGene:713:C1QB|NCBIGene:640:BLK|NCBIGene:6696:SPP1|NCBIGene:221895:JAZF1|NCBIGene:3500:IGHG1|NCBIGene:3684:ITGAM|NCBIGene:3586:IL10|NCBIGene:51284:TLR7|NCBIGene:11277:TREX1|NCBIGene:1380:CR2|NCBIGene:2215:FCGR3B|NCBIGene:7332:UBE2L3|NCBIGene:55024:BANK1|NCBIGene:4204:MECP2|NCBIGene:720:C4A|NCBIGene:3654:IRAK1|NCBIGene:721:C4B|NCBIGene:5133:PDCD1|NCBIGene:7292:TNFSF4|NCBIGene:3663:IRF5|NCBIGene:7128:TNFAIP3|NCBIGene:6775:STAT4|NCBIGene:1773:DNASE1|NCBIGene:1493:CTLA4|NCBIGene:26191:PTPN22|NCBIGene:79932:KIAA0319L|NCBIGene:3123:HLA-DRB1|NCBIGene:10318:TNIP1|NCBIGene:2113:ETS1|NCBIGene:2213:FCGR2B|NCBIGene:54899:PXK|NCBIGene:8651:SOCS1|NCBIGene:139818:DOCK11|NCBIGene:4067:LYN
HP:0033554,Anti-Mi2 antibody positivity,The presence of autoantibodies in the blood circulation that react against the Mi-2 antigen.,,,ORPHA:221,
HP:0033555,Anti-Ro/SS-A antibody positivity,The presence of autoantibodies in the blood circulation that react against Ro/SSA autoantigens.,Anti-Ro/SSA antibody positivity,,ORPHA:206572|ORPHA:596448|ORPHA:289390|ORPHA:163525,
HP:0033556,Anti-nucleoporin 62 antibody positivity,The presence of autoantibodies (immunoglobulins) in the serum that react against nucleoporin 62.,Anti-p62 antibody positivity,,ORPHA:536,NCBIGene:640:BLK|NCBIGene:6696:SPP1|NCBIGene:221895:JAZF1|NCBIGene:3500:IGHG1|NCBIGene:3684:ITGAM|NCBIGene:3586:IL10|NCBIGene:51284:TLR7|NCBIGene:11277:TREX1|NCBIGene:1380:CR2|NCBIGene:2215:FCGR3B|NCBIGene:7332:UBE2L3|NCBIGene:55024:BANK1|NCBIGene:4204:MECP2|NCBIGene:720:C4A|NCBIGene:3654:IRAK1|NCBIGene:721:C4B|NCBIGene:5133:PDCD1|NCBIGene:7292:TNFSF4|NCBIGene:3663:IRF5|NCBIGene:7128:TNFAIP3|NCBIGene:6775:STAT4|NCBIGene:1773:DNASE1|NCBIGene:1493:CTLA4|NCBIGene:26191:PTPN22|NCBIGene:79932:KIAA0319L|NCBIGene:3123:HLA-DRB1|NCBIGene:10318:TNIP1|NCBIGene:2113:ETS1|NCBIGene:2213:FCGR2B|NCBIGene:54899:PXK
HP:0033557,Anti-proteinase 3 antibody positivity,The presence of autoantibodies in the blood circulation that react against proteinase 3. Proteinase 3 (PR3) antigen is a 29-kD serine protease that exists as a protein triplet in human neutrophils,Anti-PR3 antibody positivity,,ORPHA:183|ORPHA:900|ORPHA:727,NCBIGene:3115:HLA-DPB1|NCBIGene:26191:PTPN22|NCBIGene:1493:CTLA4|NCBIGene:5657:PRTN3|NCBIGene:3113:HLA-DPA1
HP:0033558,Anti-histone antibody positivity,The presence of autoantibodies in the blood circulation that react against histone antigens.,,,ORPHA:163525,
HP:0033559,Anti-myeloperoxidase antibody positivity,The presence of autoantibodies in the blood circulation that react against myeloperoxidase.,Anti-MPO antibody positivity|Anti-myeloperoxidase specific antineutrophil cytoplasmic antibody|MPO-ANCA,,ORPHA:91414|ORPHA:183|ORPHA:900|ORPHA:727|OMIM:233450,NCBIGene:1499:CTNNB1|NCBIGene:3115:HLA-DPB1|NCBIGene:26191:PTPN22|NCBIGene:1493:CTLA4|NCBIGene:5657:PRTN3|NCBIGene:3113:HLA-DPA1
HP:0033560,Anti-PM-Scl antibody positivity,"Anti-PM-Scl antibodies target components of RNA-processing exosome complex in the nucleolus. There are ten proteins in this complex and antibodies to eight of them are found at varying frequencies; PM/Scl-100, PM/Scl-75, hRrp4, hRrp42, hRrp46, hCs14, hRrp41, and hRrp40.",Anti-PM/Scl antibody positivity,,ORPHA:90291|ORPHA:206572,
HP:0033561,Anti-bactericidal/permeability-increasing protein antibody positivity,"The presence of autoantibodies in the blood circulation that react against bactericidal/permeability-increasing protein (BPI). BPI is an endotoxin-binding host protein with important antibacterial effects against Gram-negative bacteria, such as Pseudomonas aeruginosa. BPI is a 55 kDalton protein that is most abundant in the azurophilic granules of neutrophils. BPI also acts as a target antigen for antineutrophil cytoplasmic autoantibodies.",Anti-BPI antibody positivity,,,
HP:0033562,Anti-glycoprotein-210 antibody positivity,The presence of autoantibodies (immunoglobulins) in the serum that react against glycoprotein-210.,Anti-gp210 antibody positivity,,ORPHA:562639,
HP:0033563,Anti-tissue transglutaminase antibody positivity,The presence of autoantibodies (immunoglobulins) in the serum that react against tissue transglutaminase.,Anti-tTG antibody positivity,,ORPHA:1656|OMIM:240300,NCBIGene:326:AIRE
HP:0033565,Anti-epidermal transglutaminase antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against epidermal transglutaminase.,Anti-TG3 antibody|Anti-eTG antibody positivity|Anti-epidermal transglutaminase (anti-eTG) antibody|Anti-keratinocyte transglutaminase,,ORPHA:1656,
HP:0033572,Anti-H1 antibody positivity,The presence of autoantibodies in the blood circulation that react against histone H1.,,,,
HP:0033573,Anti-H4 antibody positivity,The presence of autoantibodies in the blood circulation that react against histone H4.,,,,
HP:0033574,Anti-H3 antibody positivity,The presence of autoantibodies in the blood circulation that react against histone H3.,,,,
HP:0033575,Anti-H2A antibody positivity,The presence of autoantibodies in the blood circulation that react against histone H2A.,,,,
HP:0033576,Anti-H2B antibody positivity,The presence of autoantibodies in the blood circulation that react against histone H2B.,,,,
HP:0033592,Anti-H3-H4 antibody positivity,The presence of autoantibodies in the blood circulation that react against the H3-H4 histone dimer.,,,,
HP:0033593,Anti-H2A-H2B antibody positivity,The presence of autoantibodies in the blood circulation that react against the H2A-H2B histone dimer.,,,,
HP:0033629,IgG4 autoimmune antibody positivity,The presence of an antibody of subclass IgG4 in the blood circulation that is directed against the organism's own cells or tissues.,,,,
HP:0033637,Anti-endomysial antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against endomysial tissue transglutaminase 2 (tTG2).,Anti-transglutaminase 2 antibody positivity,,ORPHA:1656|OMIM:240300,NCBIGene:326:AIRE
HP:0033708,Anti-3-hydroxy- 3-methylglutaryl-coA reductase antibody positivity,,Anti-3-hydroxy- 3-methylglutaryl-coA reductase antibodies|Anti-HMGCR autoantibodies,,ORPHA:206569,
HP:0033713,Anti-signal recognition particle antibody positivity,The presence of autoantibodies (immunoglobulins) in the serum that react against anti-signal recognition particle.,Anti-SRP antibody positivity,,ORPHA:732|ORPHA:206569,
HP:0034001,Anti-Complement factor H antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against complement factor H.,CFH autoantibodies,,,
HP:0034002,Anti-phospholipase A2 receptor antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against the phospholipase A2 receptor.,Anti-PLA2R antibody positivity,,ORPHA:97560,
HP:0034016,Anti-HLA antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against a human leukocyte antigen (HLA).,Anti-human leukocyte antigen antibody positivity,,OMIM:620757,NCBIGene:10020:GNE
HP:0034017,Anti-class I HLA antibody positivity,"The presence of autoantibodies (immunoglobulins) in the blood circulation that react against a class I human leukocyte antigen (HLA). Class I HLA corresponds to MHC class I (A, B, and C).",,,,
HP:0034018,Anti-class II HLA antibody positivity,"The presence of autoantibodies (immunoglobulins) in the blood circulation that react against a class II human leukocyte antigen (HLA). Class I HLA corresponds to MHC class II (DP, DM, DO, DQ, and DR).",,,,
HP:0034019,Anti-HLA-A antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against a human leukocyte antigen-A (HLA-A).,,,,
HP:0034020,Anti-HLA-A IgG1 antibody positivity,The presence of IgG1 autoantibodies in the blood circulation that react against a human leukocyte antigen-A (HLA-A).,,,,
HP:0034021,Anti-HLA-A IgG3 antibody positivity,The presence of IgG3 autoantibodies in the blood circulation that react against a human leukocyte antigen-A (HLA-A).,,,,
HP:0034022,Anti-HLA-B antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against a human leukocyte antigen-B (HLA-B).,,,,
HP:0034023,Anti-HLA-B IgG1 antibody positivity,The presence of IgG1 autoantibodies in the blood circulation that react against a human leukocyte antigen-B (HLA-B).,,,,
HP:0034024,Anti-HLA-B IgG3 antibody positivity,The presence of IgG3 autoantibodies in the blood circulation that react against a human leukocyte antigen-B (HLA-B).,,,,
HP:0034055,Anti-side-chain cleavage enzyme antibody positivity,"The presence of autoantibodies (immunoglobulins) in the serum that react against cytochrome P450 cholesterol side-chain cleavage enzyme (P450scc), which is encoded by CYP11A1 cytochrome P450 family 11 subfamily A member 1 (Gene ID:1583).",Anti-P450scc,,ORPHA:3453|OMIM:240300|ORPHA:85138,NCBIGene:326:AIRE
HP:0034061,Anti-steroid 17alpha-hydroxylase antibody positivity,The presence of autoantibodies (immunoglobulins) in the serum that react against steroid 17alpha-hydroxylase.,Anti-P450C17,,ORPHA:3143|ORPHA:85138,
HP:0034062,Anti-insulin antibody positivity,The presence of autoantibodies (immunoglobulins) in the serum that react against insulin.,IAA positivity|Insulin autoantibodies,,OMIM:621004|ORPHA:3002,NCBIGene:5133:PDCD1|NCBIGene:9103:FCGR2C
HP:0034063,Anti-islet antigen-2 antibody positivity,The presence of autoantibodies (immunoglobulins) in the serum that react against tyrosine phosphatase IA-2.,Anti-IA2 antibody positivity|Anti-IA2A|ICA512,,OMIM:616192|OMIM:620044|ORPHA:3002|OMIM:621004,NCBIGene:5611:DNAJC3|NCBIGene:1854:DUT|NCBIGene:9103:FCGR2C|NCBIGene:5133:PDCD1
HP:0034064,Anti-salivary protein antibody positivity,The presence of autoantibodies (immunoglobulins) in the serum that react against salivary protein.,Anti-SP1 antibody positivity,,ORPHA:289390,
HP:0034065,Anti-Zinc transporter 8 antibody positivity,The presence of autoantibodies (immunoglobulins) in the serum that react against zinc transporter 8.,Anti ZnT8 autoantibodies,,,
HP:0034066,Anti-carbonic anhydrase VI antibody positivity,The presence of autoantibodies (immunoglobulins) in the serum that react against carbonic anhydrase VI.,Anti-CA6 antibody positivity,,ORPHA:289390,
HP:0034068,Anti-plasminogen binding peptide antibody positivity,The presence of autoantibodies (immunoglobulins) in the serum that react against plasminogen binding peptide.,Anti-PBP antibody positivity,,,
HP:0034069,Anti-parotid secretory protein antibody positivity,The presence of autoantibodies (immunoglobulins) in the serum that react against parotid secretory protein.,Anti-PSP antibody positivity,,ORPHA:289390,
HP:0034070,Anti-enterocyte antibody positivity,The presence of autoantibodies (immunoglobulins) in the serum that react against enterocytes.,AEA,,,
HP:0034071,Anti-21-hydroxylase antibody positivity,The presence of autoantibodies (immunoglobulins) in the serum that react against 21-hydroxylase.,Anti-P450c21,,ORPHA:85138|OMIM:240300|ORPHA:3453,NCBIGene:326:AIRE
HP:0034076,Anti-ribosome Po antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against ribosome Po.,,,ORPHA:536|ORPHA:90002|ORPHA:289390|ORPHA:809,NCBIGene:640:BLK|NCBIGene:6696:SPP1|NCBIGene:221895:JAZF1|NCBIGene:3500:IGHG1|NCBIGene:3684:ITGAM|NCBIGene:3586:IL10|NCBIGene:51284:TLR7|NCBIGene:11277:TREX1|NCBIGene:1380:CR2|NCBIGene:2215:FCGR3B|NCBIGene:7332:UBE2L3|NCBIGene:55024:BANK1|NCBIGene:4204:MECP2|NCBIGene:720:C4A|NCBIGene:3654:IRAK1|NCBIGene:721:C4B|NCBIGene:5133:PDCD1|NCBIGene:7292:TNFSF4|NCBIGene:3663:IRF5|NCBIGene:7128:TNFAIP3|NCBIGene:6775:STAT4|NCBIGene:1773:DNASE1|NCBIGene:1493:CTLA4|NCBIGene:26191:PTPN22|NCBIGene:79932:KIAA0319L|NCBIGene:3123:HLA-DRB1|NCBIGene:10318:TNIP1|NCBIGene:2113:ETS1|NCBIGene:2213:FCGR2B|NCBIGene:54899:PXK
HP:0034077,Anti-complement component C1q antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against C1q.,Anti-C1q antibody positivity,,ORPHA:536,NCBIGene:640:BLK|NCBIGene:6696:SPP1|NCBIGene:221895:JAZF1|NCBIGene:3500:IGHG1|NCBIGene:3684:ITGAM|NCBIGene:3586:IL10|NCBIGene:51284:TLR7|NCBIGene:11277:TREX1|NCBIGene:1380:CR2|NCBIGene:2215:FCGR3B|NCBIGene:7332:UBE2L3|NCBIGene:55024:BANK1|NCBIGene:4204:MECP2|NCBIGene:720:C4A|NCBIGene:3654:IRAK1|NCBIGene:721:C4B|NCBIGene:5133:PDCD1|NCBIGene:7292:TNFSF4|NCBIGene:3663:IRF5|NCBIGene:7128:TNFAIP3|NCBIGene:6775:STAT4|NCBIGene:1773:DNASE1|NCBIGene:1493:CTLA4|NCBIGene:26191:PTPN22|NCBIGene:79932:KIAA0319L|NCBIGene:3123:HLA-DRB1|NCBIGene:10318:TNIP1|NCBIGene:2113:ETS1|NCBIGene:2213:FCGR2B|NCBIGene:54899:PXK
HP:0034078,Anti-centromere protein A antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against CENP-A.,Anti-CENP-A antibody positivity,,ORPHA:90291,
HP:0034079,Anti-centromere protein B antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against CENP-B.,Anti-CENP-B antibody positivity,,ORPHA:90291,
HP:0034080,Anti-U3 RNP antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against U3 RNP.,Anti-fibrillarin antibody positivity,,ORPHA:90291,
HP:0034081,Anti-Th/To antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against Th/To.,,,ORPHA:90291,
HP:0034082,Anti-bicaudal D2 antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against bicaudal D2.,Anti-BICD2 antibody positivity,,ORPHA:90291,
HP:0034083,Anti-nucleolus-organizing region antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against Nor90.,Anti-Nor90 antibody positivity,,ORPHA:90291,
HP:0034084,Anti-phosphatidyl ethanolamine antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against phosphatidyl ethanolamine.,,,ORPHA:80|ORPHA:464343,
HP:0034085,Anti-PM-Scl100 antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against PM-Scl100.,,,ORPHA:90291,
HP:0034086,Anti-PM-Scl75 antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against PM-Scl75.,,,ORPHA:90291,
HP:0034087,Anti-U11/U12 RNP antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against U11/U12 RNP.,,,ORPHA:90291,
HP:0034088,Anti-Ku antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against Ku.,,,ORPHA:90291|ORPHA:206572,
HP:0034089,Anti-B23 antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against B23.,,,ORPHA:90291,
HP:0034090,Anti-RuvBL1/2 antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against RuvBL1/2.,,,ORPHA:90291,
HP:0034091,Anti-platelet derived growth factor receptor,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against platelet derived growth factor receptor.,Anti-PDGFR antibody positivity,,ORPHA:90291,
HP:0034092,Anti-cyclic citrullinated peptide antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against cyclic citrullinated peptide.,Anti-CCP antibody positivity,,ORPHA:809,
HP:0034093,Anti-Ro52/TRIM21 antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against Ro52/TRIM21.,Anti-Ro52 antibody positivity,,ORPHA:289390|ORPHA:90002|ORPHA:809|ORPHA:90291|ORPHA:206572|ORPHA:536|ORPHA:562639,NCBIGene:640:BLK|NCBIGene:6696:SPP1|NCBIGene:221895:JAZF1|NCBIGene:3500:IGHG1|NCBIGene:3684:ITGAM|NCBIGene:3586:IL10|NCBIGene:51284:TLR7|NCBIGene:11277:TREX1|NCBIGene:1380:CR2|NCBIGene:2215:FCGR3B|NCBIGene:7332:UBE2L3|NCBIGene:55024:BANK1|NCBIGene:4204:MECP2|NCBIGene:720:C4A|NCBIGene:3654:IRAK1|NCBIGene:721:C4B|NCBIGene:5133:PDCD1|NCBIGene:7292:TNFSF4|NCBIGene:3663:IRF5|NCBIGene:7128:TNFAIP3|NCBIGene:6775:STAT4|NCBIGene:1773:DNASE1|NCBIGene:1493:CTLA4|NCBIGene:26191:PTPN22|NCBIGene:79932:KIAA0319L|NCBIGene:3123:HLA-DRB1|NCBIGene:10318:TNIP1|NCBIGene:2113:ETS1|NCBIGene:2213:FCGR2B|NCBIGene:54899:PXK
HP:0034094,Anti-angiotensin receptor type-1 antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against angiotensin receptor type-1.,Anti-AT1R antibody positivity,,ORPHA:90291,
HP:0034095,Anti-endothelin-1 type A receptor antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against endothelin-1 type A receptor.,Anti-ETAR antibody positivity,,ORPHA:90291,
HP:0034096,Anti-phosphatidic acid antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against phosphatidic acid.,,,ORPHA:536,NCBIGene:640:BLK|NCBIGene:6696:SPP1|NCBIGene:221895:JAZF1|NCBIGene:3500:IGHG1|NCBIGene:3684:ITGAM|NCBIGene:3586:IL10|NCBIGene:51284:TLR7|NCBIGene:11277:TREX1|NCBIGene:1380:CR2|NCBIGene:2215:FCGR3B|NCBIGene:7332:UBE2L3|NCBIGene:55024:BANK1|NCBIGene:4204:MECP2|NCBIGene:720:C4A|NCBIGene:3654:IRAK1|NCBIGene:721:C4B|NCBIGene:5133:PDCD1|NCBIGene:7292:TNFSF4|NCBIGene:3663:IRF5|NCBIGene:7128:TNFAIP3|NCBIGene:6775:STAT4|NCBIGene:1773:DNASE1|NCBIGene:1493:CTLA4|NCBIGene:26191:PTPN22|NCBIGene:79932:KIAA0319L|NCBIGene:3123:HLA-DRB1|NCBIGene:10318:TNIP1|NCBIGene:2113:ETS1|NCBIGene:2213:FCGR2B|NCBIGene:54899:PXK
HP:0034097,Anti-phosphatidyl choline antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against phosphatidyl choline.,,,ORPHA:80|ORPHA:464343,
HP:0034098,Anti-phosphatidyl glycerol antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against phosphatidyl glycerol.,,,ORPHA:80|ORPHA:464343,
HP:0034099,Anti-phosphatidyl inositol antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against phosphatidyl inositol.,,,ORPHA:80|ORPHA:464343,
HP:0034100,Anti-phosphatidyl serine antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against phosphatidyl serine.,,,ORPHA:80|ORPHA:464343,
HP:0034101,Anti-annexin-V antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against annexin-V.,,,ORPHA:80|ORPHA:464343,
HP:0034102,Anti-sphingolipid antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against sphingolipids.,,,ORPHA:548,
HP:0034103,Anti-GM1 antibody positivity,"Ganglioside-monosialic acid (GM1) is a type of glycosphingolipid with one sialic acid. GM1 is located on the outer layer of the plasma membrane, and plays a vital role in neurogenesis, nerve development, differentiation and repair after injury",Anti-ganglioside-monosialic acid antibody positivity,,,
HP:0034104,Anti-neutrophil elastase antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against neutrophil elastase.,,,ORPHA:900|ORPHA:727|ORPHA:183,NCBIGene:3115:HLA-DPB1|NCBIGene:26191:PTPN22|NCBIGene:1493:CTLA4|NCBIGene:5657:PRTN3|NCBIGene:3113:HLA-DPA1
HP:0034105,Anti-transcription intermediary factor-1gamma antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against transcription intermediary factor-1gamma.,Anti-TIF-1gamma antibody positivity|Anti-TIF1-gamma antibody positivity,,ORPHA:221,
HP:0034106,Anti-Su antigen/argonaute 2 antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against Su antigen/argonaute 2.,Anti-Ago2 antibody positivity|Anti-Su antibody positivity,,,
HP:0034107,Anti-p53 antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against p53.,,,ORPHA:562639,
HP:0034108,Anti-Y-box protein-1 antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against Y-box protein-1.,Anti-YB 1 antibody positivity,,ORPHA:562639,
HP:0034109,Anti-GW182 antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against GW182.,,,,
HP:0034110,Anti-Gerbich phenotype 1 antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against Ge-1.,Anti-Ge-1 antibody positivity,,ORPHA:562639,
HP:0034111,Anti-MIT3 antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against MIT3.,,,ORPHA:562639,
HP:0034112,Anti-GM1 IgG antibody positivity,The presence of IgG autoantibodies (immunoglobulins) in the blood circulation that react against GM1.,,,,
HP:0034114,Anti-hexokinase-1 antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against hexokinase-1.,Anti-HK-1 antibody positivity,,ORPHA:562639,
HP:0034115,Anti-Kelch like protein 12 antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against Kelch like protein 12.,Anti-KLHL-12 antibody positivity,,ORPHA:562639,
HP:0034117,Anti-angiotensin-converting enzyme 2 antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against angiotensin-converting enzyme 2.,Anti-ACE2 antibody positivity,,ORPHA:90291,
HP:0034118,Anti-GM1 IgM antibody positivity,The presence of IgM autoantibodies (immunoglobulins) in the blood circulation that react against GM1.,,,,
HP:0034119,Anti-GD1a IgG antibody positivity,The presence of IgG autoantibodies (immunoglobulins) in the blood circulation that react against ganglioside D1a.,,,,
HP:0034120,Anti-GD1a IgM antibody positivity,The presence of IgM autoantibodies (immunoglobulins) in the blood circulation that react against ganglioside D1a.,,,,
HP:0034121,Anti-GD1a antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against ganglioside D1a.,,,,
HP:0034122,Anti-GQ1b antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against ganglioside Q1b.,,,ORPHA:98919,
HP:0034123,Anti-GQ1b IgM antibody positivity,The presence of IgM autoantibodies (immunoglobulins) in the blood circulation that react against ganglioside Q1b.,,,,
HP:0034124,Anti-GD1b antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against GD1b ganglioside.,,,,
HP:0034125,Anti-GD1b IgM antibody positivity,The presence of IgM autoantibodies (immunoglobulins) in the blood circulation that react against GD1b ganglioside.,,,,
HP:0034126,Anti-GD1b IgG antibody positivity,The presence of IgG autoantibodies (immunoglobulins) in the blood circulation that react against GD1b ganglioside.,,,,
HP:0034127,Anti-GQ1b IgG antibody positivity,The presence of IgG autoantibodies (immunoglobulins) in the blood circulation that react against ganglioside Q1b.,,,,
HP:0034128,Anti-GT1a antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against T1a ganglioside.,,,,
HP:0034129,Anti-GT1a IgM antibody positivity,The presence of IgM autoantibodies (immunoglobulins) in the blood circulation that react against T1a ganglioside.,,,,
HP:0034130,Anti-GT1a IgG antibody positivity,The presence of IgG autoantibodies (immunoglobulins) in the blood circulation that react against T1a ganglioside.,,,,
HP:0034131,Anti-GT1b antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against T1b ganglioside.,,,,
HP:0034132,Anti-GM2 antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against ganglioside GM2.,,,,
HP:0034133,Anti-GM3 antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against ganglioside GM3.,,,,
HP:0034134,Anti-GM4 antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against ganglioside GM4.,,,,
HP:0034135,Anti-neurofascin-155 antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against NF155.,Anti-NF155 antibody positivity,,ORPHA:2932,
HP:0034136,Anti-neurofascin 186 antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against NF186.,Anti-NF186 antibody positivity,,ORPHA:2932,
HP:0034137,Anti-contactin-1 antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against CNTN1.,Anti-CNTN1 antibody positivity,,ORPHA:2932,
HP:0034138,Anti-contactin-associated protein 1 antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against anti-contactin-associated protein 1.,Anti-CASPR1 antibody positivity,,ORPHA:2932,
HP:0034139,Anti-SUMO-activating enzyme antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against SAE.,Anti-SAE antibody positivity|Anti-small ubiquitin-like modifier-1 activating enzyme antibody positivity,,ORPHA:221,
HP:0034140,Anti-SUMO-activating enzyme subunit 1 antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against SAE 1.,,,ORPHA:221,
HP:0034141,Anti-SUMO-activating enzyme subunit 2 antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against SAE 2.,Anti-SAE 2 antibody positivity,,ORPHA:221,
HP:0034142,Anti-nuclear matrix protein-2 antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against NXP-2.,Anti-MJ/NXP-2 antibody positivity|Anti-NXP-2 antibody positivity,,ORPHA:221,
HP:0034143,Anti-threonyl-tRNA synthetase antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against threonyl-tRNA synthetase.,Anti-PL-7 antibody positivity,,ORPHA:732|ORPHA:81,
HP:0034144,Anti-hY-RNA complex antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against Ro60.,Anti-Ro60 antibody positivity,,,
HP:0034145,Anti-alanyl-tRNA synthetase antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against alanyl-tRNA synthetase.,Anti-PL-12 antibody positivity,,ORPHA:81|ORPHA:732,
HP:0034146,Anti-glycyl tRNA-synthetase antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against glycyl tRNA-synthetase.,Anti-EJ antibody positivity,,ORPHA:81|ORPHA:732,
HP:0034147,Anti-aminoacyl-tRNA synthetase antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against a tRNA synthetase enzyme.,,,ORPHA:732|ORPHA:81|ORPHA:221,
HP:0034148,Anti-isoleucyl tRNA-synthetase antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against isoleucyl tRNA-synthetase.,Anti-OJ antibody positivity,,ORPHA:732|ORPHA:81,
HP:0034149,Anti-phenylalanyl tRNA synthetase antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against phenylalanyl tRNA synthetase.,Anti-Zo alpha antibody positivity|Anti-Zo antibody positivity|Phenylanyl-t-RNA synthetase alpha antibody positivity,,ORPHA:732|ORPHA:81,
HP:0034150,Anti-tyrosyl-tRNA synthetase antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against tyrosyl-tRNA synthetase.,Anti-Ha antibody positivity,,ORPHA:81|ORPHA:732,
HP:0034151,Anti-asparaginyl-tRNA synthetase antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against asparaginyl-tRNA synthetase.,Anti-KS antibody positivity,,ORPHA:81|ORPHA:732,
HP:0034152,Anti-histidyl tRNA synthetase antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against histidyl tRNA synthetase.,Anti-JO1 antibody positivity|Anti-Jo-1 antibody positivity,,ORPHA:81|ORPHA:732|ORPHA:221,
HP:0034153,Anti-cytosolic-5-nucleotidase-1A antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against cytosolic-5-nucleotidase-1A (cN1A).,Anti-cN1A antibody positivity,,ORPHA:611|ORPHA:81,
HP:0034154,Anti-Ki antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against Ki.,,,,
HP:0034155,Anti-sp100 antibody positivity,"The presence of autoantibodies (immunoglobulins) in the serum that react against sp100. Autoantibodies causing the MND pattern are directed against sp100, sp140, promyelocytic leukemia nuclear body proteins (PML) or ubiquitin-like modifier (SUMO) proteins, while in the punctate nuclear envelope pattern, the target antigens are gp210, nucleoporin-62 or laminin B receptor proteins.",,,ORPHA:562639,
HP:0034156,Anti-beta-2-Glycoprotein I IgG antibody positivity,Presence of IgG antibodies against beta 2 glycoprotein I in the circulation. Beta-2 glycoprotein I (beta2GPI) is the principal target of autoantibodies in the antiphospholipid syndrome.,Anti-beta2GPI IgG antibody positivity,,OMIM:618048|ORPHA:80,NCBIGene:51371:POMP
HP:0034157,Anti-beta-2-Glycoprotein I IgM antibody positivity,Presence of IgM antibodies against beta 2 glycoprotein I in the circulation. Beta-2 glycoprotein I (beta2GPI) is the principal target of autoantibodies in the antiphospholipid syndrome.,Anti-beta2GPI IgM antibody positivity,,ORPHA:80,
HP:0034158,Anti-tyrosine phosphatase region of islet antigen-2 antibody positivity,The presence of autoantibodies (immunoglobulins) in the serum that react against the tyrosine phossphatase region of islet antigen 2A (this region is a specific part of IA-2). Usually IA-2A are measured using the intracellular portion of IA-2 (IA-2ic) made up of the protein tyrosine phosphatase (PTP) and juxtamembrane (JM) regions.,Anti-PTPA antibody positivity,,,
HP:0034189,Anti-thyroid-stimulating hormone receptor antibody positivity,The presence of autoantibodies (immunoglobulins) in the serum that react against thyroid-stimulating hormone.,Anti-TSH receptor antibody positivity|Anti-thyrotropin receptor antibody|TRAbs,,OMIM:240300|ORPHA:3002|OMIM:274300,NCBIGene:326:AIRE|NCBIGene:9103:FCGR2C|NCBIGene:7068:THRB
HP:0034257,C4 nephritic factor positivity,"The presence of autoantibodies (immunoglobulins) in the blood circulation that recognize C4b2a, the C3 convertase of the classical pathway of complement.",,,,
HP:0430050,Anti-thyroid antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against one or more components on the thyroid.,Antithyroid antibody positivity,,OMIM:241850|ORPHA:95719|ORPHA:566243|OMIM:274300|OMIM:618534|OMIM:618048|OMIM:619632|OMIM:609152|OMIM:615577|ORPHA:3002|OMIM:240300|OMIM:301109|ORPHA:64744|ORPHA:277|ORPHA:525731|ORPHA:49041|ORPHA:95715|ORPHA:37042|ORPHA:228426|OMIM:610199|OMIM:620376,NCBIGene:2304:FOXE1|NCBIGene:7068:THRB|NCBIGene:10125:RASGRP1|NCBIGene:51371:POMP|NCBIGene:29775:CARD10|NCBIGene:7253:TSHR|NCBIGene:4791:NFKB2|NCBIGene:9103:FCGR2C|NCBIGene:326:AIRE|NCBIGene:139818:DOCK11|NCBIGene:100:ADA|NCBIGene:50943:FOXP3|NCBIGene:83737:ITCH|NCBIGene:169792:GLIS3|NCBIGene:4067:LYN
HP:4000013,Anti-desmoglein-1 antibody positivity,"The presence of autoantibodies (immunoglobulins) in the serum that react against desmoglein-1, a dermal cell adhesion molecule.",,,ORPHA:704,
HP:4000014,Anti-desmoglein-3 antibody positivity,"The presence of autoantibodies (immunoglobulins) in the serum that react against desmoglein-3, a dermal cell adhesion molecule.",,,ORPHA:704,
HP:4000015,Anti-envoplakin antibody positivity,"The presence of autoantibodies (immunoglobulins) in the serum that react against envoplakin, a cytoskeletal linker protein that links intermediate filaments to cellular junctions.",,,,
HP:4000016,Anti-periplakin antibody positivity,The presence of autoantibodies (immunoglobulins) in the serum that react against periplakin.,,,,
HP:4000017,Anti-desmoplakin I antibody positivity,The presence of autoantibodies (immunoglobulins) in the serum that react against desmoplakin-1.,,,,
HP:4000018,Anti-desmoplakin II antibody positivity,The presence of autoantibodies (immunoglobulins) in the serum that react against desmoplakin-II.,,,,
HP:4000019,Anti-BP230 antibody positivity,The presence of autoantibodies (immunoglobulins) in the serum that react against BP230.,,,ORPHA:703,NCBIGene:3119:HLA-DQB1|NCBIGene:3123:HLA-DRB1
HP:4000020,Anti-BP180 antibody positivity,The presence of autoantibodies (immunoglobulins) in the serum that react against BP180.,,,ORPHA:703,NCBIGene:3119:HLA-DQB1|NCBIGene:3123:HLA-DRB1
HP:4000021,Anti-laminin 332 antibody positivity,The presence of autoantibodies (immunoglobulins) in the serum that react against laminin-332.,Anti-laminin 5 antibody positivity,,,
HP:4000022,Anti-laminin 6 antibody positivity,The presence of autoantibodies (immunoglobulins) in the serum that react against laminin-6.,,,,
HP:4000023,Anti-laminin gamma1 antibody positivity,The presence of autoantibodies (immunoglobulins) in the serum that react against laminin gamma-1.,,,,
HP:4000024,Anti-laminin antibody positivity,The presence of autoantibodies (immunoglobulins) in the serum that react against a laminin. Laminins are major components of the basement membrane.,,,,
HP:4000025,Anti-integrin antibody positivity,"The presence of autoantibodies (immunoglobulins) in the serum that react against an integrin. Integrins are a family of cell adhesion molecules with 24 known integrin heterodimers. Integrins transduce mechanical and biochemical signals from fibrotic extracellular matrix into the cell, activate latent TGFbeta, and subsequently modulate fibroblast adhesion, migration, and growth.",,,OMIM:301109,NCBIGene:139818:DOCK11
HP:4000026,Anti-transglutaminase 6 antibody,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against transglutaminase 6.,,,ORPHA:1656,
HP:4000027,Anti-LAD-1 antibody positivity,"The presence of autoantibodies (immunoglobulins) in the serum that react against LAD-1, which is the soluble 120 kDa ectodomain of BP180.",,,ORPHA:46488,
HP:4000028,Anti-LABD97 antibody positivity,"The presence of autoantibodies (immunoglobulins) in the serum that react against LABD97, which is structurally identical to a portion of the extracellular domain of BPAg2. BPAg2, a 180 kDa bullous pemphigoid antigen, is a transmembrane protein important for basement membrane cohesion.",,,ORPHA:46488,
HP:4000029,Antigliadin antibody positivity,The presence of autoantibodies (immunoglobulins) in the serum that react against gliadin.,AGA autoantibodies,,ORPHA:1656,
HP:4000030,Anti-reticulin antibody positivity,The presence of autoantibodies (immunoglobulins) in the serum that react against reticulin.,,,ORPHA:1656|OMIM:240300,NCBIGene:326:AIRE
HP:4000031,Anti-type VII collagen antibody,The presence of autoantibodies (immunoglobulins) in the serum that react against collagen type VII.,,,ORPHA:1656|OMIM:301109,NCBIGene:139818:DOCK11
HP:4000170,Anti-platelet antigen antibody positivity,"The presence of autoantibodies (immunoglobulins) in the serum that react against antigens present on the surface of thrombocytes such as the glycoproteins GPIIb/IIIa, GPIb/IX, and GPIa/IIa.",Antiplatelet antibodies present,,ORPHA:3002|OMIM:620475|ORPHA:90291|OMIM:620757,NCBIGene:9103:FCGR2C|NCBIGene:60:ACTB|NCBIGene:10020:GNE
HP:4000171,Anti-voltage-gated potassium channel antibody positivity,The presence of autoantibodies (immunoglobulins) in the serum that react against a voltage-gated potassium channel.,Voltage gated potassium channel antibodies in blood,,ORPHA:90291,
HP:5000000,Anti-AK5 antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against anti-adenylate kinase 5 (AK5).,,,,
HP:5000001,Anti-AMPAR antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against anti-alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR).,Anti-alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antibody,,,
HP:5000002,Anti-Amphiphysin antibody,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against Amphiphysin.,,,ORPHA:443804|ORPHA:1183|ORPHA:3198,
HP:5000003,Anti-ARHGAP26 antibody,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against Rho GTPase-activating protein 26 (ARHGAP26).,Anti-Ca antibody|Anti-RhoGTPase-activating protein 26 antibody,,,
HP:5000004,Anti-CARP VIII antibody,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against Carbonic anhydrase-related protein VIII (CARPVIII).,Anti CARPVIII antibody|Anti-carbonic anhydrase-related protein VIII antibody,,,
HP:5000005,Anti-CASPR2,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against contactin-associated protein-like 2 (CASPR2).,Anti-Caspr2 antibody|Anti-contactin-associated protein-like 2 antibody,,ORPHA:623615|ORPHA:84142|ORPHA:83467,
HP:5000006,Anti-CV2/CRMP5 antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against CV2/CRMP5. Anti-CV2/CRMP5 autoantibody is the most commonly detected anti-neuronal autoantibody. Patients with typical paraneoplastic chorea show fully developed chorea in the course of weeks to months with acute inflammation in the striatum.,Anti-CV2 antibody|Anti-CV2/collapsin response mediator protein (CRMP)5 antibody|Anti-collapsin response-mediated protein 5 antibody,,ORPHA:623626,
HP:5000007,Anti-DPPX antibody,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against dipeptidyl-peptidase-like protein 6 (DPPX).,Anti-dipeptidyl-peptidase-like protein 6 antibody,,ORPHA:3198|ORPHA:443804,
HP:5000008,Anti-FGFR3 antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against FGFR3.,Anti-fibroblast growth factor receptor 3 antibody,,,
HP:5000009,Anti-GABA(A)R antibody,"The presence of autoantibodies (immunoglobulins) in the blood circulation that react against gamma-aminobutyric acid A receptor, i.e., GABA(A)R.",Anti-GABAA R antibody|Anti-gamma amino butyric acid type A receptors antibody,,,
HP:5000010,Anti-GABA(B)R antibody,"The presence of autoantibodies (immunoglobulins) in the blood circulation that react against gamma-aminobutyric acid B receptor, i.e., GABA(B)R.",Anti-gamma-aminobutyric acid B receptor antibody,,ORPHA:623615,
HP:5000011,Anti-GAD65 antibody,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against glutamic acid decarboxylase 65 (GAD65).,Anti-glutamic acid decarboxylase 65 antibody,,OMIM:240300|OMIM:616033|ORPHA:3198,NCBIGene:326:AIRE|NCBIGene:93587:TRMT10A
HP:5000012,Anti-Gephyrin antibody,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against Gephyrin.,,,ORPHA:3198|ORPHA:443804,
HP:5000013,Anti-GFAP antibody,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against glial fibrillary acidic protein (GFAP).,Anti-glial fibrillary acidic protein antibody,,ORPHA:139417,
HP:5000014,Anti-GlyR antibody,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against Glycine receptor (GlyR).,Anti-glycine receptor antibody,,ORPHA:3198,
HP:5000015,Anti-Homer-3 antibody,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against Homer-3.,Anti-Homer protein homolog 3 antibody,,,
HP:5000016,Anti-Hu antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against Hu.,Anti-ANNA-1 antibody|Anti-Neuronal Nuclear Antibody type-1 antibody,,ORPHA:623615|ORPHA:208999|ORPHA:623626,
HP:5000017,Anti-Iglon5 antibody,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against immunoglobulin-like cell adhesion molecule 5 (IgLON5).,Anti-immunoglobulin-like cell adhesion molecule 5 antibody,,,
HP:5000018,Anti-ITPR1 antibody,"The presence of autoantibodies (immunoglobulins) in the blood circulation that react against inositol 1,4,5-trisphosphate receptor 1 (ITPR1).","Anti-inositol 1,4,5-trisphosphate receptor type 1 antibody",,,
HP:5000019,Anti-Kelch like protein 11 antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against kelch-like protein 11 (KLHL11).,Anti-KLHL11 antibody,,,
HP:5000020,Anti-LGI1 antibody,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against leucine-rich glioma-inactivated 1 (LGI1).,Anti-Anti-leucine-rich glioma-inactivated 1 antibody,,ORPHA:623615,
HP:5000021,Anti-Ma antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against Ma.,,,,
HP:5000022,Anti-Ma2 antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against Ma2.,Anti-Ta antibody,,,
HP:5000023,Anti-Ma1 antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against Ma1.,,,,
HP:5000024,Anti-mGluR1 antibody,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against metabotropic glutamate receptor 1 (mGluR1).,Anti-metabotropic glutamate receptor 1 antibody,,ORPHA:623626,
HP:5000025,Anti-mGluR5 antibody,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against metabotropic glutamate receptor 5 (mGluR5).,Anti-Metabotropic Glutamate Receptor Type 5 antibody,,,
HP:5000026,Anti-neurexin-3alpha antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against neurexin-3alpha.,Anti-neurexin-3alpha antibody,,,
HP:5000027,Anti-P/Q-type VGCC antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against P/Q-type voltage-gated calcium channels (VGCCs).,Anti-P/Q-type voltage-gated calcium-channel antibody,,ORPHA:43393,
HP:5000028,Anti-MAP1B antibody,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against microtubule-associated protein 1B (MAP1B).,Anti-Purkinje cell cytoplasmic type-2 antibody|Anti-microtubule-associated protein 1B antibody,,,
HP:5000029,Anti-PKCgamma antibody,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against protein kinase Cgamma.,Anti-Protein kinase C gamma antibody,,,
HP:5000030,Anti-Ri antibody,"The presence of autoantibodies (immunoglobulins) in the blood circulation that react against Ri, an antineuronal antibody.",Anti-ANNA-2 antibody,,ORPHA:623626,
HP:5000031,Anti-Septin-5 antibody,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against Septin-5.,,,,
HP:5000032,Anti-SEZ6L2 antibody,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against seizure-related 6 homolog like 2 (SEZ6L2).,,,,
HP:5000033,Anti-SOX1 antibody,"The presence of autoantibodies (immunoglobulins) in the blood circulation that react against SOX1. Anti-SOX1 antibodies, also known as antiglial nuclear antibody (AGNA), are specifically found in paraneoplastic neurological disorders. Since SOX1 is expressed in neuronal precursor cells in the developing central nervous system, it has been used as an early marker of neural stem cells.",Anti-Sry-like high mobility group box (SOX) 1 antibody,,,
HP:5000034,Anti-Tr/DNER antibody,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against Tr/DNER. Anti-Tr antibodies are directed against cerebellar Purkinje cells (termed anti-Tr or PCA-Tr). Anti-Tr autoantibodies are frequently associated with Hodgkin lymphoma (HL). Anti-Tr antibodies are defined by a specific staining pattern in cerebellar tissue that is characterized by punctate immunoreactivity in both the dendritic tree and soma of Purkinje cells but not in their axons. This characteristic pattern is indicative of the presence of anti-Tr antibodies. The Delta/Notch-like epidermal growth factor-related receptor (DNER) was identified as the target antigen of anti-Tr.,Anti-delta/notch-like epidermal growth factor-related receptor antibody|PCA-Tr,,ORPHA:623626,
HP:5000035,Anti-TRIM46 antibody,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against the axon initial segment protein tripartite motif 46 (TRIM46).,,,,
HP:5000036,Anti-TRIM9/TRIM67 antibody,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against TRIM9/TRIM67.,,,,
HP:5000037,Anti-Yo antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against Yo.,Anti-Purkinje cell cytoplasmic antibody 1,,ORPHA:623626,
HP:5000038,Anti-titin antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against titin.,,,ORPHA:589|ORPHA:536,NCBIGene:640:BLK|NCBIGene:6696:SPP1|NCBIGene:221895:JAZF1|NCBIGene:3500:IGHG1|NCBIGene:3684:ITGAM|NCBIGene:3586:IL10|NCBIGene:51284:TLR7|NCBIGene:11277:TREX1|NCBIGene:1380:CR2|NCBIGene:2215:FCGR3B|NCBIGene:7332:UBE2L3|NCBIGene:55024:BANK1|NCBIGene:4204:MECP2|NCBIGene:720:C4A|NCBIGene:3654:IRAK1|NCBIGene:721:C4B|NCBIGene:5133:PDCD1|NCBIGene:7292:TNFSF4|NCBIGene:3663:IRF5|NCBIGene:7128:TNFAIP3|NCBIGene:6775:STAT4|NCBIGene:1773:DNASE1|NCBIGene:1493:CTLA4|NCBIGene:26191:PTPN22|NCBIGene:79932:KIAA0319L|NCBIGene:3123:HLA-DRB1|NCBIGene:10318:TNIP1|NCBIGene:2113:ETS1|NCBIGene:2213:FCGR2B|NCBIGene:54899:PXK
HP:5000039,Anti-Zic4 antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against Zic family member 4 (ZIC4).,,,,
HP:5000042,Anti-Sj/ITPR1 antibody,"The presence of autoantibodies (immunoglobulins) in the blood circulation that react against Sj/inositol 1,4,5-trisphosphate receptor.","Anti-Sj/inositol 1,4,5-trisphosphate receptor antibody",,,
HP:5000043,Anti-D2 R antibody,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against dopamine-2 receptor.,Anti-dopamine-2 receptors (D2R) antibody,,,
HP:5000044,Anti-GluK2 antibody,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against glutamate kainate receptor subunit 2 (GluK2).,Anti-glutamate kainate receptor subunit 2 antibody,,,
HP:5000046,Anti-Lrp4 antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against low-density lipoprotein receptor (Lrp4).,Anti-low-density lipoprotein receptor-related protein 4 antibody,,ORPHA:589,
HP:5000047,Anti-ryanodine receptor antibody,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against ryanodine receptor.,Anti-RyR antibody,,ORPHA:589,
HP:5000048,Anti-Kv1.4 antibody,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against the voltage-gated potassium channel Kv1.4.,,,ORPHA:589,
HP:6000186,Anti-soluble liver antigen/liver pancreas antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against soluble liver antigen.,Anti-SLA/LP,,,
HP:6000187,Anti-thrombospondin type I domain-containing 7A antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against thrombospondin type I domain-containing 7A.,Anti-THSD7A antibody|Anti-THSD7A antibody present in blood,,,
HP:6000188,Antisperm antibody positivity,The presence of autoantibodies (immunoglobulins) in the serum that react against sperm antigens.,,,,
HP:6000193,Anti-osteoprotegerin antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against osteoprotegerin.,Anti-OPG antibody positivity,,,
HP:6000343,Antiparietal cell antibody positivity,The presence of autoantibodies (immunoglobulins) in the serum that react against parietal cell antigens.,,,OMIM:240300,NCBIGene:326:AIRE
HP:6000344,Anti-intrinsic factor antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against intrinsic factor.,,,,
HP:6000347,Anti-NR2A antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against the N-Methyl-D-aspartate (NMDA) receptor NR2A subunit.,,,,
HP:6000351,Anti-coagulation factor antibody positivity,The presence of an antibody in the blood circulation that is directed against a coagulation factor.,,,,
HP:6000380,Anti-perilipin-1 antibody positivity,The presence of autoantibodies in the serum that react against perilipin-1 (PLIN1).,,,,
HP:6000386,Positive cold agglutinin test,"Cold agglutinin are erythrocyte antibodies which possess the property of agglutinating red blood cells at temperatures of below 37 degrees C, this phenomenon is reversible after heating.",,,,
HP:6000387,Anti-D-L antibody positivity,The presence of Donath-Landsteiner (D-L) autoantibodies (immunoglobulins) in the serum.,Anti-Donath-Landsteiner antibody positivity,,,
HP:6000388,Anti-erythrocyte autoantibody positivity,The presence of an antibody in the blood circulation that is directed against an antigen on the surface of erythrocytes (red-blood cells).,Antierythrocyte autoantibody positivity,,ORPHA:90033|ORPHA:71275,NCBIGene:6006:RHCE|NCBIGene:6007:RHD|NCBIGene:6005:RHAG
HP:6000448,Anti-desmocollin antibody positivity,The presence of autoantibodies (immunoglobulins) in the serum that react against desmocollin.,,,,
HP:6000462,Anti-ADAMTS13 antibody positivity,"The presence of autoantibodies (immunoglobulins) in the blood circulation that react against A Disintegrin and Metalloprotease with ThromboSpondin type 1 repeats, member 13 (ADAMTS13).",,,,
HP:6000475,Anti-beta fodrin antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against a component of beta-fodrin.,,,,
HP:6000491,Anti-prothrombin antibody positivity,The presence of autoantibodies (immunoglobulins) in the serum that react against prothrombin.,Anti-FII antibody positivity,,,
HP:6000492,Anti-factor V antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against factor V.,Anti-FV antibody positivity,,,
HP:6000493,Anti-factor VII antibody positivity,The presence of autoantibodies (immunoglobulins) in the serum that react against factor VII.,Anti-FVII antibody positivity,,,
HP:6000494,Anti-factor VIII antibody positivity,The presence of autoantibodies (immunoglobulins) in the serum that react against factor VIII.,Anti-FVIII antibody positivity,,,
HP:6000495,Anti-factor IX antibody positivity,The presence of autoantibodies (immunoglobulins) in the serum that react against factor IX.,Anti-FIX antibody positivity,,,
HP:6000496,Anti-factor X antibody positivity,The presence of an antibody in the blood circulation that is directed against factor X.,Anti-FX antibody positivity,,,
HP:6000497,Anti-factor XI antibody positivity,The presence of an antibody in the blood circulation that is directed against factor XI.,Anti-FXI antibody positivity,,,
HP:6000498,Anti-factor XIII antibody positivity,The presence of an antibody in the blood circulation that is directed against factor XIII.,Anti-FXIII antibody positivity,,,
HP:6000499,Anti-factor H antibody positivity,The presence of an antibody in the blood circulation that is directed against factor H.,Anti-FH antibody positivity,,,
HP:6000508,Anti-human ferritin peptide antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against the human ferritin peptide.,,,,
HP:6000643,Anti-lamin A antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against lamin A.,LMNA antibody positivity|PCNA antibody positivity|Prelamin A antibody positivity|ki-67 antibody positivity,,,
HP:6000644,Anti-lamin C antibody positivity,The presence of autoantibodies in the blood circulation that react against human lamin C.,Prelamin C antibody positivity,,,
HP:6000645,Anti-vinculin antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against vinculin.,,,,
HP:6000646,Anti-annexin A5 antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against annexin A5.,,,,
HP:6000676,Anti-von Willebrand factor antibody positivity,The presence of autoantibodies in the serum that react to von Willebrand factor (VWF).,,,,
HP:6000678,Myositis-specific autoantibody positivity,"The presence of autoantibodies (immunoglobulins) in the serum that display a high degree of specificity for idiopathic inflammatory myopathy (myositis-specific autoantibodies (MSAs)). MSAs are clinically useful biomarkers to help the diagnosis of polymyositis/dermatomyositis (PM/DM). Many of these are also associated with a unique clinical subset of PM/DM, making them useful in predicting and monitoring certain clinical manifestations.",,,ORPHA:81|ORPHA:732|ORPHA:221,
HP:6000795,Anti-folate receptor antibody positivity,The presence of autoantibodies (immunoglobulins) in the serum that react against the folate receptor in the blood circulation.,,,,
HP:6000876,Anti-Glutamate Receptor delta2 antibody positivity,The presence of autoantibodies in the serum that react against glutamate receptor delta2.,,,,
HP:6000877,Anti-dachshund family transcription factor 1 antibody positivity,The presence of autoantibodies in the serum that react against dachshund-homolog 1 (DACH1) autoantigen.,Anti-neuronal nuclear antibody-type 3 positivity,,,
HP:6000878,Anti-potassium channel tetramerization domain containing 16 antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against potassium channel tetramerization domain containing 16 (KCTD16).,Anti-KCTD16,,,
HP:6000879,Anti-regulator of G protein signaling 8 antibody positivity,The presence of autoantibodies in the serum that react against regulator of G-protein signaling 8 (RGS8).,,,,
HP:6000880,Anti-neurochondrin antibody positivity,The presence of autoantibodies in the serum that react against neurochondrin .,,,,
HP:6000881,Anti-DCC netrin 1 receptor antibody positivity,The presence of autoantibodies in the serum that react against Netrin-1 receptors DCC (deleted in colorectal carcinoma).,,,,
HP:6000882,Anti-recoverin antibody positivity,The presence of autoantibodies in the serum that react against recoverin. Recoverins are calcium-binding proteins primarily expressed in retinal rod photoreceptors and primarily involved in phototransduction.,Anti-retinal CAR antigen antibody,,,
HP:6001015,Anti-HLA-DQ antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against a human leukocyte antigen (HLA-DQ). DQ is one of several antigens involved in antibody-mediated rejection of organ transplants.,,,,
HP:6001058,Anti-neuronal intermediate filament antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against neuronal intermediate filament.,,,,
HP:6001059,Anti-DREBRIN antibody positivity,The presence of autoantibodies in the serum that react against dendritic spine scaffolding protein Drebrin.,,,,
HP:6001060,Anti-lipoprotein lipase autoantibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against anti-lipoprotein lipase.,Anti-LPL autoantibody positivity,,,
HP:6001061,Anti-apolipoprotein CII autoantibody positivity,The presence of autoantibodies in the blood circulation that react against apoCII.,Anti-apoCII autoantibody positivity,,,
HP:6001064,Anti-acetylcholine receptor antibody positivity,The presence of autoantibodies (immunoglobulins) in the blood circulation that react against acetylcholine receptor.,,,OMIM:616313|OMIM:616325|OMIM:616323|OMIM:616227|OMIM:254300|ORPHA:589|OMIM:614198|ORPHA:99867|ORPHA:79480|OMIM:254210|OMIM:603034|OMIM:616224|ORPHA:590|OMIM:616314|OMIM:601462|OMIM:608930|ORPHA:98914|ORPHA:254361|OMIM:616326|OMIM:616324,NCBIGene:1140:CHRNB1|NCBIGene:4593:MUSK|NCBIGene:1144:CHRND|NCBIGene:199857:ALG14|NCBIGene:285489:DOK7|NCBIGene:6329:SCN4A|NCBIGene:1103:CHAT|NCBIGene:8292:COLQ|NCBIGene:9581:PREPL|NCBIGene:1134:CHRNA1|NCBIGene:1305:COL13A1|NCBIGene:6616:SNAP25|NCBIGene:4649:MYO9A|NCBIGene:6843:VAMP1|NCBIGene:375790:AGRN|NCBIGene:60482:SLC5A7|NCBIGene:6572:SLC18A3|NCBIGene:6576:SLC25A1|NCBIGene:127833:SYT2|NCBIGene:5339:PLEC|NCBIGene:5913:RAPSN|NCBIGene:1145:CHRNE